Dr. Navin Verma, MD

Dr. Verma practices at Neurological Services of Orlando PA in Orlando, Florida.

Dr. Verma's NPI, 1962524884, was assigned on April 3, 2007. Dr. Verma graduated from Ross University School of Medicine in 2002. Dr. Verma holds Florida license ME102384.

Dr. Verma's primary practice is Neurological Services of Orlando PA, at 3849 Oakwater Cir, Orlando, FL 32806 in Orange County. The practice phone is (407) 240-1762.

Dr. Verma's primary practice is Neurological Services of Orlando PA in Orlando, Florida. Dr. Verma is also affiliated with AdventHealth Orlando. The medical group on file is Orlando Health Medical Group. Dmand AI also links Dr. Verma to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Verma practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Verma's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Verma is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Verma's licenses on file in 3 states: Florida, New York and New Jersey.

Dmand AI lists cerebrovascular disease, hypersomnia, parkinson's disease, restless legs syndrome and sleep apnea among the conditions Dr. Verma treats.

CMS data shows 2,614 Medicare services from Dr. Verma across 10 procedure codes in 2024, for 772 Medicare patients. Medicare paid $207,264 for them. Every service was in an office.

CMS counts 772 Medicare patients who saw Dr. Verma in 2024. The largest group is 65 to 74, with 413 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.16, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Verma's median patient age at 57, with 42% women.

In 2024, Dr. Verma wrote 159 Medicare Part D claims for 56 patients. 94% of them were for generic drugs. CMS names the drug for 99 of them, across 5 drugs with 11 or more claims each, at $788 in total drug cost. In 2023, CMS named 127 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Verma for performance year 2024, reported individually. Dr. Verma accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Verma as offering telehealth.

Dmand AI links 85 papers to Dr. Verma, published from 2009 to 2025. 2018 was the busiest year, with 9. The most frequent topics are T-Lymphocytes, Signal Transduction and Cells, Cultured. Dr. Verma has published most often in Methods Mol Biol. Dr. Verma's most frequent co-authors are Kurian George Chandy, Nasrollah Ghahramani, MD and Muhammad Abdulbasit, FACP, MD.

Dmand AI links Dr. Verma to 1 clinical trial. Conditions studied include Agnosia and Perceptual Disorders.

CMS Open Payments shows 1,380 general payments to Dr. Verma from 80 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 91% of the total. Sanofi and Genzyme US Companies paid the most, $1,831.

Dmand AI lists 2 awards for Dr. Verma, most recently Best Doctors in 2022.

Dr. Verma graduated from Ross University School of Medicine in 2002. Dr. Verma is a member of AAN and AASM.

Dr. Verma is in network with 14 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.